HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

Abstract
Minimal residual disease (MRD) assessment is standard in many hematologic malignancies but is considered investigational in multiple myeloma (MM). We report a prospective analysis of the prognostic importance of MRD detection by multiparameter flow cytometry (MFC) in 295 newly diagnosed MM patients uniformly treated in the GEM2000 protocol VBMCP/VBAD induction plus autologous stem cell transplantation [ASCT]). MRD status by MFC was determined at day 100 after ASCT. Progression-free survival (PFS; median 71 vs 37 months, P < .001) and overall survival (OS; median not reached vs 89 months, P = .002) were longer in patients who were MRD negative versus MRD positive at day 100 after ASCT. Similar prognostic differentiation was seen in 147 patients who achieved immunofixation-negative complete response after ASCT. Moreover, MRD(-) immunofixation-negative (IFx(-)) patients and MRD(-) IFx(+) patients had significantly longer PFS than MRD(+) IFx(-) patients. Multivariate analysis identified MRD status by MFC at day 100 after ASCT as the most important independent prognostic factor for PFS (HR = 3.64, P = .002) and OS (HR = 2.02, P = .02). Our findings demonstrate the clinical importance of MRD evaluation by MFC, and illustrate the need for further refinement of MM re-sponse criteria. This trial is registered at http://clinicaltrials.gov under identifier NCT00560053.
AuthorsBruno Paiva, Maria-Belén Vidriales, Jorge Cerveró, Gema Mateo, Jose J Pérez, Maria A Montalbán, Anna Sureda, Laura Montejano, Norma C Gutiérrez, Alfonso García de Coca, Natalia de Las Heras, Maria V Mateos, Maria C López-Berges, Raimundo García-Boyero, Josefina Galende, Jose Hernández, Luis Palomera, Dolores Carrera, Rafael Martínez, Javier de la Rubia, Alejandro Martín, Joan Bladé, Juan J Lahuerta, Alberto Orfao, Jesús F San Miguel, GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups
JournalBlood (Blood) Vol. 112 Issue 10 Pg. 4017-23 (Nov 15 2008) ISSN: 1528-0020 [Electronic] United States
PMID18669875 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Bleomycin
  • Mitomycin
  • Vincristine
  • Dexamethasone
  • Doxorubicin
  • Cisplatin
  • Carmustine
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
  • Bleomycin (administration & dosage)
  • Carmustine (administration & dosage)
  • Cisplatin (administration & dosage)
  • Dexamethasone (administration & dosage)
  • Disease-Free Survival
  • Doxorubicin (administration & dosage)
  • Female
  • Flow Cytometry (methods)
  • Humans
  • Male
  • Middle Aged
  • Mitomycin (administration & dosage)
  • Multiple Myeloma (blood, diagnosis, mortality, therapy)
  • Neoplasm, Residual
  • Predictive Value of Tests
  • Stem Cell Transplantation (methods)
  • Survival Rate
  • Transplantation, Autologous
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: